LOG IN
SIGN UP
MARKET
ONCT
ONCT
Oncternal Therapeutics Inc
NASDAQ
Real-time Quotes | Nasdaq Last Sale
0.8188
+0.0358
+4.57%
After Hours: 0.8188 0 0.00% 16:00 05/26 EDT
OPEN
0.7900
PREV CLOSE
0.7830
HIGH
0.8482
LOW
0.7701
VOLUME
187.97K
TURNOVER
0
52 WEEK HIGH
5.88
52 WEEK LOW
0.6902
MARKET CAP
40.47M
P/E (TTM)
-1.1463
1D
5D
1M
3M
1Y
5Y
Oncternal Therapeutics To Present At ASCO Jun. 4
Updated MCL and CLL data from the CIRLL study are encouraging and continue to improve ORR of 85% (23 of 27 evaluable patients) and CR rate of 41% (11 of 27 evaluable patients) for patients with MCL treated with
Benzinga · 9m ago
Oncternal Therapeutics Presents Updated Interim Data For Zilovertamab In Combination With Ibrutinib At ASCO 2022
Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASCO 2022 Updated MCL and CLL data from the CIRLL study are encouraging and continue to improve ORR
Benzinga · 9m ago
Here's Why We're Watching Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Simply Wall St. · 05/17 11:40
--Maxim Initiates Oncternal Therapeutics at Buy, Sets Price Target at $3.50
MT Newswires · 05/10 10:53
Oncternal Therapeutics GAAP EPS of -$0.20 beats by $0.04, revenue of $0.7M beats by $0.17M
Oncternal Therapeutics press release (NASDAQ:ONCT): Q1 GAAP EPS of -$0.20 beats by $0.04. Revenue of $0.7M (-6.7% Y/Y) beats by $0.17M. As of March 31, 2022, ONCT had ~49.4 million
Seekingalpha · 05/05 20:38
Oncternal Therapeutics's Earnings Outlook
Oncternal Therapeutics (NASDAQ:ONCT) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Oncternal Therapeutics will report an earnings per share (E...
Benzinga · 05/04 20:34
66 Biggest Movers From Yesterday
Gainers Better Therapeutics, Inc. (NASDAQ: BTTX) shares surged 120.4% to close at $2.01 on Monday following a 5% drop on Friday.
Benzinga · 05/03 10:08
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 02, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted an inducement award to one new e...
GlobeNewswire · 05/02 21:00
No Data
Learn about the latest financial forecast of ONCT. Analyze the recent business situations of Oncternal Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 6 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ONCT stock price target is 9.58 with a high estimate of 15.00 and a low estimate of 3.500.
Current 0.8188
EPS
Actual
Estimate
-0.20-0.15-0.10-0.05
Institutional Holdings
Institutions: 95
Institutional Holdings: 13.34M
% Owned: 26.99%
Shares Outstanding: 49.43M
TypeInstitutionsShares
Increased
22
702.03K
New
17
418.06K
Decreased
25
1.22M
Sold Out
11
447.87K
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.99%
Pharmaceuticals & Medical Research
+0.43%
Key Executives
Non-Executive Chairman/Independent Director
David Hale
President/Chief Executive Officer/Director
James Breitmeyer
Chief Financial Officer/Treasurer/Secretary
Richard Vincent
Chief Scientific Officer
Gunnar Kaufmann
General Counsel
Chase Leavitt
Other
Salim Yazji
Director
Robert Wills
Director
Nakanishi Xin
Independent Director
Michael Carter
Independent Director
Daniel Kisner
Independent Director
William LaRue
Independent Director
Rosemary Mazanet
Independent Director
Charles Theuer
No Data
No Data
About ONCT
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of cancers with unmet medical need. The Company’s clinical pipeline includes cirmtuzumab, TK216, ROR1 CAR-T. Cirmtuzumab is a monoclonal antibody that is designed to inhibit Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1) for the treatment of patients with B-cell lymphoid malignancies, including mantle cell lymphoma (MCL), and chronic lymphocytic leukemia (CLL). TK216 is a small molecule inhibiting the biological activity of E26 transformation-specific (ETS)-family transcription factor oncoproteins. The Company is also developing a ROR1-targeted CAR-T cell therapy candidate utilizing the binding domain of cirmtuzumab as a single-chain variable region fragment (scFv) for the treatment of patients with hematological malignancies or solid tumors.
Webull offers kinds of Oncternal Therapeutics Inc stock information, including NASDAQ:ONCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCT stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading ONCT stock methods without spending real money on the virtual paper trading platform.